0
Critical Care: Late-Breaking Abstracts: Clinical Pulmonary and Critical Care Medicine |

Efficacy and Safety of Cordyceps for Chinese Patients With Stable and GOLD Stage 2-3 COPD: Systematic Review and Meta-analysis FREE TO VIEW

Xuhua Yu, PhD; Yuquan Mao, MS; Tony Zhang, PhD; Ruifeng Chen, MD; Shaonan Liu, MS; Lei Wu, MD; Yuanbin Chen, MS; Xinfeng Guo, PhD; Lin Lin, MS; Yinji Xu, MS; Charlie Changli Xue, PhD
Author and Funding Information

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A176. doi:10.1016/j.chest.2016.02.182
Text Size: A A A
Published online

SESSION TITLE: Late-Breaking Abstracts: Clinical Pulmonary and Critical Care Medicine

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, April 17, 2016 at 01:00 PM - 02:00 PM

PURPOSE: Cordyceps is often used in China as an alternative pharmaceutical care to treat chronic obstructive pulmonary disease (COPD). Some random control trails have been conducted to assessed effect of Cordyceps used for COPD, but no systematic review and meta-analysis was reported.

METHODS: Electrical databases (CNKI, VIP, Wanfang database, CBM, Pubmed, Embase, Cochrane) were searched for eligible randomized controlled trials up to June 2015. FEV1%pre, FEV1/FVC, six minute walking test (6MWT), St George’s Respiratory Questionnaire (SGRQ), exacerbations, effective rate and adverse events were as main assessed outcome measures. Effect estimates were pooled with fix-effects meta-analysis if I2<50% in sensitivity analysis, or else with a random-effects model. Evidence was synthesized in a narrative review where meta-analysis was not possible.

RESULTS: Searches yielded 2437 records, and 10 observational studies were meet the determined including criteria, and 349 out of 692 COPD patients were assessed. Meta analysis showed that Cordyceps preparation increased FEV1%pre (MD 2.65, 95%CI 1.72-3.57) (only when Cordyceps preparation plus routine care versus routine care), FEV1/FVC (MD 6.16, 95%CI 4.83-7.48), six minute walk distance (MD 34.08, 95%CI 26.09-42.07), risk of effectiveness (OR 3.17, 95%CI 1.77-7.88) and reduce SGRQ scores (MD 9.35, 95%CI-12.51--6.19), acute exacerbations (MD 1.58, 95%CI 95%CI -2.18--0.98). No serious adverse events was reported.

CONCLUSIONS: Benefits of Cordyceps preparation for stable COPD with GOLD stage 2-3 were promising, even though there’s some methodological weaknesses. More long-term and sizable sample random control trail are required to support our view for further.

CLINICAL IMPLICATIONS: Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable disease, which is characterized by persistent airflow limitation because of the enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. And COPD has been one of the major cause of chronic morbidity and mortality throughout the world. However, effect of Bronchodilators and Inhaled gluocoprednisomes remain less satisfactory. Cordyceps is one of fungus which grows up in high attitude area. In China, it was used broadly in COPD patients to help to alleviate symptoms and improve their quality of lives. So in this study we index citations on cordyceps treating stable COPD with Gold stage 2 to 3, and review them systematically by meta-analysis to evaluate its efficacy and safety.

DISCLOSURE: The following authors have nothing to disclose: Xuhua Yu, Yuquan Mao, Tony Zhang, Ruifeng Chen, Shaonan Liu, Lei Wu, Yuanbin Chen, Xinfeng Guo, Lin Lin, Yinji Xu, Charlie Changli Xue

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Safety of technoshere insulin. Curr Drug Saf Published online Aug 29, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543